--- title: "U.S. stock market midday update: Sonoma Pharma down 12.83%, trading volume increased, market sentiment fluctuations attract attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/283547740.md" description: "Sonoma Pharma fell 12.83%; Eli Lilly fell 1.67%, with a transaction volume of USD 2.677 billion; Johnson & Johnson fell 2.28%, with a transaction volume of USD 1.49 billion; Merck fell 3.92%, with a transaction volume of USD 971 million; AstraZeneca fell 1.97%, with a market value of USD 305.2 billion" datetime: "2026-04-21T19:08:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283547740.md) - [en](https://longbridge.com/en/news/283547740.md) - [zh-HK](https://longbridge.com/zh-HK/news/283547740.md) --- # U.S. stock market midday update: Sonoma Pharma down 12.83%, trading volume increased, market sentiment fluctuations attract attention **U.S. Stock Market Midday Update** Sonoma Pharma, down 12.83%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Eli Lilly down 1.67%, with increased trading volume. Based on recent key news: 1. On April 20, Eli Lilly announced the acquisition of Kelonia Therapeutics for up to $7 billion, strengthening its position in the blood cancer treatment field. This move shows Eli Lilly's active expansion in the biotech sector, which may change the market competitive landscape. Source: Caixin. 2. On April 20, tensions between the U.S. and Iran and rising oil prices put pressure on U.S. stocks, with major indices opening lower and investor sentiment cautious. Geopolitical risks continue to affect the market. Source: Wall Street Insight. 3. On April 20, Hanwei United announced the sale of its productivity solutions and services business, showing that companies are actively adjusting their business structures in the face of market uncertainties. Source: Zhitong Finance. Johnson & Johnson down 2.28%. Based on recent key news: 1. On April 21, CNBC host Jim Cramer advised investors to avoid chasing high-flying tech stocks and instead focus on fundamentally sound stocks like Johnson & Johnson. Cramer pointed out that Johnson & Johnson is under pressure due to external factors such as litigation risks, but its fundamentals remain competitive. This advice led investors to reassess Johnson & Johnson's investment value, causing the stock price to drop. 2. On April 21, Johnson & Johnson showcased its latest innovations in arrhythmia care at the HRS 2026 conference, including the launch of the CARTOSOUND SONATA module. Despite this innovation demonstrating the company's technological strength, the market reaction was tepid, failing to boost the stock price. 3. On April 21, Johnson & Johnson's stock price has performed poorly over the past year, with a low of $146.115 per share and a high of $251.71 per share, currently trading at $230.69. The stock price volatility reflects market concerns about its long-term performance. Geopolitical risks and rising oil prices affect market sentiment. Merck down 3.92%, with increased trading volume. Based on recent key news: 1. On April 21, Merck's combination treatment for kidney cancer with Eisai failed to meet the primary endpoint of late-stage studies, leading to a drop in stock price. The study tested the combination of Merck's Keytruda, Welireg, and Eisai's Lenvima, which did not significantly extend survival or delay cancer progression. 2. On April 21, sales of Merck's HPV vaccine Gardasil saw a significant decline, impacting sales and profit expectations for 2026, further pressuring the stock price. 3. On April 21, the U.S. FDA approved Merck's HIV treatment Idvynso; however, despite this positive news, it failed to offset the impact of other negative factors on the stock price. The pharmaceutical industry faces R&D challenges, with significant capital outflows **Stocks Ranked Among the Top by Market Capitalization in the Industry** AstraZeneca fell by 1.97%. Based on recent key news: 1. On April 21, AstraZeneca announced that its drug Ultomiris achieved its primary endpoint in a Phase III clinical trial, significantly reducing proteinuria levels in adult patients with IgA nephropathy. This news led to a 1.15% drop in stock price. Source: Reuters 2. On April 20, AstraZeneca's targeted IL-33 biologic tozorakimab achieved positive results in a pivotal Phase III clinical trial, significantly reducing the acute exacerbation rate of chronic obstructive pulmonary disease. This news had a positive impact on the stock price. Source: Jinshi Data 3. On April 20, analysts rated AstraZeneca as "Moderate Buy," but believed that five other stocks had greater investment value. This rating may affect investor confidence. Source: Jinshi Data The pharmaceutical industry has made significant progress in clinical trials ### Related Stocks - [SNOA.US](https://longbridge.com/en/quote/SNOA.US.md) ## Related News & Research - [Eli Lilly stock: Next stop $2,000?](https://longbridge.com/en/news/286829092.md) - [Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals](https://longbridge.com/en/news/286789989.md) - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md) - [Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report](https://longbridge.com/en/news/286951567.md) - [Lilly Reports Positive Topline Data From Phase III Obesity Study Of Retatrutide](https://longbridge.com/en/news/287212210.md)